Study of low-dose radiation followed by immunotherapy and chemotherapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new sequence of treatments for advanced stomach cancer that has spread to the lining of the abdomen. You would first get low-dose radiation, then a combination of immunotherapy, chemotherapy, and a special type of chemotherapy delivered directly into the belly, to see if it can control the cancer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to give consent.
- You have a certain type of stomach cancer (adenocarcinoma) that is HER2-negative.
- The cancer has spread to the lining of your abdomen (peritoneum), and a scan or fluid sample shows this clearly.
- You have already tried one type of chemotherapy (platinum-based) and it didn't work or caused too many side effects.
- You need to be in reasonably good health (able to do daily activities) and have adequate organ function, especially for your kidney, liver, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This trial tests a new treatment for stomach or colon cancer that has spread to the lining of the abdomen. It combines low-dose radiation with a type of immunotherapy called NIPS to help your body fight the cancer. The goal is to see if this combination can shrink the tumors and improve outcomes.
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Hear when a new Gastric Cancer Peritoneal Metastasis (GCPM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.